MRK Stock Cash Flow Statements

Merck & Co. Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Merck & Co. Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31

cash flows from operating activities
net income	4,429,000,000	5,085,000,000	3,744,000,000	3,161,000,000	5,461,000,000	4,767,000,000		4,750,000,000	-5,972,000,000	2,825,000,000								3,186,000,000	-2,091,000,000	2,944,000,000	3,010,000,000	3,219,000,000	2,363,000,000	1,908,000,000	2,644,000,000	2,862,000,000	1,778,000,000	1,958,000,000	1,716,000,000	741,000,000	-1,038,000,000	-51,000,000	1,951,000,000	1,556,000,000	-587,000,000	2,189,000,000	1,209,000,000	1,130,000,000	982,000,000	1,831,000,000	688,000,000	958,000,000	7,327,000,000	843,000,000	2,033,000,000	1,731,000,000	815,000,000	1,151,000,000	1,543,000,000	1,724,000,000	2,054,000,000	1,071,000,000	-500,000,000	371,600,000	780,200,000	330,200,000	805,000,000		589,000,000	435,000,000	291,000,000
adjustments to reconcile net income to net cash from operating activities:
amortization	601,000,000	597,000,000	675,000,000	633,000,000	614,000,000	473,000,000	462,000,000	562,000,000	477,000,000	543,000,000	462,000,000	460,000,000	464,000,000	699,000,000	405,000,000	360,000,000	337,000,000	534,000,000
depreciation	518,000,000	502,000,000	522,000,000	553,000,000	518,000,000	511,000,000	502,000,000	452,000,000	426,000,000	448,000,000	430,000,000	499,000,000	474,000,000	421,000,000	430,000,000	399,000,000	353,000,000	396,000,000
income from investments in equity securities	-99,000,000	-90,000,000		31,000,000	-57,000,000	-143,000,000									-405,000,000
charge for research and development asset acquisition
deferred income taxes	-448,000,000	-186,000,000	-616,000,000	-401,000,000	-181,000,000	-51,000,000	-931,000,000	-336,000,000	-355,000,000	-277,000,000	-307,000,000	-661,000,000	-262,000,000	-338,000,000	159,000,000	-1,000,000	39,000,000	-10,000,000	-715,000,000	-75,000,000	40,000,000	82,000,000	-170,000,000	-237,000,000	-343,000,000	194,000,000	-118,000,000	-133,000,000	-228,000,000	-30,000,000	-2,020,000,000	-329,000,000	-218,000,000	-54,000,000	-1,456,000,000	55,000,000	-50,000,000	-70,000,000	82,000,000	-463,000,000	-204,000,000	-179,000,000	-827,000,000	-527,000,000	-942,000,000	-304,000,000	202,000,000	-213,000,000	-563,000,000	-133,000,000	-627,000,000	-214,000,000	-349,200,000	-423,900,000	-471,100,000	152,200,000
share-based compensation	216,000,000	195,000,000	187,000,000	195,000,000	203,000,000	176,000,000	167,000,000	164,000,000	169,000,000	145,000,000	145,000,000	139,000,000	137,000,000	120,000,000	119,000,000	117,000,000	123,000,000	120,000,000	121,000,000	125,000,000	121,000,000	108,000,000	111,000,000	102,000,000	111,000,000	93,000,000	87,000,000	91,000,000	90,000,000	80,000,000	80,000,000	76,000,000	82,000,000	74,000,000	75,000,000	77,000,000	80,000,000	68,000,000	78,000,000	75,000,000	83,000,000	63,000,000	69,000,000	75,000,000	78,000,000	56,000,000	66,000,000	68,000,000	82,000,000	87,000,000	107,000,000	93,000,000	109,500,000	125,300,000	141,800,000	132,400,000
other	335,000,000	109,000,000	-101,000,000	437,000,000	91,000,000	83,000,000	449,000,000	-99,000,000	202,000,000	-197,000,000	132,000,000	393,000,000	633,000,000	143,000,000	306,000,000	1,025,000,000	-195,000,000	-331,000,000	396,000,000	-243,000,000	-345,000,000	143,000,000	-35,000,000	105,000,000	-6,000,000	120,000,000	393,000,000	156,000,000	379,000,000	50,000,000	300,000,000	-94,000,000	91,000,000	-28,000,000	66,000,000	50,000,000	100,000,000	97,000,000	60,000,000	120,000,000	26,000,000	551,000,000	-45,000,000	142,000,000	-77,000,000	-115,000,000	112,000,000	-85,000,000	530,000,000	249,000,000	-234,000,000	-222,000,000	-66,600,000	6,600,000	249,000,000	188,000,000	2,000,000
net changes in assets and liabilities	-2,259,000,000	-3,712,000,000		2,582,000,000	-1,012,000,000	-3,382,000,000		2,177,000,000	-1,636,000,000	-2,890,000,000		263,000,000	-1,399,000,000	-1,299,000,000		-139,000,000	-1,551,000,000	-2,104,000,000		-1,445,000,000	-527,000,000	-3,666,000,000		-91,000,000	-443,000,000	-2,935,000,000		-760,000,000	199,000,000	-1,473,000,000		-2,922,000,000	198,000,000	-2,535,000,000		-564,000,000	-1,563,000,000	-875,000,000		223,000,000	-392,000,000	-618,000,000		2,068,000,000	-415,000,000	-703,000,000		1,315,000,000		821,000,000	-418,000,000	-1,067,000,000		787,100,000	1,058,500,000	-1,064,000,000
net cash from operating activities	3,293,000,000	2,500,000,000	3,450,000,000	9,291,000,000	5,637,000,000	3,090,000,000		7,717,000,000	3,704,000,000	1,339,000,000					-64,000,000	0	-740,000,000	1,791,000,000	4,006,000,000	2,173,000,000	3,367,000,000	707,000,000	4,794,000,000	4,226,000,000	3,084,000,000	1,336,000,000	3,592,000,000	2,793,000,000	3,382,000,000	1,155,000,000	4,015,000,000	-1,171,000,000	3,317,000,000	286,000,000	3,632,000,000	2,971,000,000	1,615,000,000	2,158,000,000	4,247,000,000	3,305,000,000	2,585,000,000	2,284,000,000	-1,164,000,000	4,348,000,000	2,315,000,000	2,361,000,000	3,026,000,000	3,949,000,000	3,233,000,000	4,577,000,000	2,852,000,000	1,721,000,000	3,539,100,000	2,591,900,000	3,324,900,000	1,366,100,000	556,000,000	599,000,000	1,191,000,000
cash flows from investing activities
capital expenditures	-764,000,000	-1,328,000,000	-937,000,000	-783,000,000	-791,000,000	-861,000,000	-989,000,000	-902,000,000	-965,000,000	-1,007,000,000	-1,149,000,000	-1,126,000,000	-1,129,000,000	-984,000,000	-1,208,000,000	-1,172,000,000	-934,000,000	-1,134,000,000	-1,514,000,000	-1,516,000,000	-668,000,000	-986,000,000	-1,137,000,000	-959,000,000	-782,000,000	-595,000,000	-929,000,000	-653,000,000	-583,000,000	-450,000,000	-715,000,000	-441,000,000	-393,000,000	-339,000,000	-551,000,000	-409,000,000	-375,000,000	-279,000,000	-493,000,000	-316,000,000	-271,000,000	-203,000,000	-490,000,000	-320,000,000	-302,000,000	-205,000,000	-429,000,000	-355,000,000	-603,000,000	-431,000,000	-365,000,000	-324,000,000	-660,300,000	-337,900,000	-337,000,000	-342,800,000	-161,000,000		-172,000,000	-195,000,000	-175,000,000
free cash flows	2,529,000,000	1,172,000,000	2,513,000,000	8,508,000,000	4,846,000,000	2,229,000,000		6,815,000,000	2,739,000,000	332,000,000					-1,272,000,000	-1,172,000,000	-1,674,000,000	657,000,000	2,492,000,000	657,000,000	2,699,000,000	-279,000,000	3,657,000,000	3,267,000,000	2,302,000,000	741,000,000	2,663,000,000	2,140,000,000	2,799,000,000	705,000,000	3,300,000,000	-1,612,000,000	2,924,000,000	-53,000,000	3,081,000,000	2,562,000,000	1,240,000,000	1,879,000,000	3,754,000,000	2,989,000,000	2,314,000,000	2,081,000,000	-1,654,000,000	4,028,000,000	2,013,000,000	2,156,000,000	2,597,000,000	3,594,000,000	2,630,000,000	4,146,000,000	2,487,000,000	1,397,000,000	2,878,800,000	2,254,000,000	2,987,900,000	1,023,300,000	395,000,000		1,019,000,000
purchases of securities and other investments	-612,000,000	-595,000,000	-455,000,000	0	-49,000,000	-15,000,000	-251,000,000	-117,000,000	-25,000,000	-562,000,000	-494,000,000	-5,000,000	-333,000,000	-372,000,000	0	0	0	-1,000,000	-17,000,000	-1,000,000	-28,000,000	-49,000,000	-822,000,000	-570,000,000	-836,000,000	-974,000,000	-1,095,000,000	-1,651,000,000	-3,922,000,000	-1,326,000,000	-2,342,000,000	-2,117,000,000	-3,351,000,000	-2,929,000,000	-5,567,000,000	-3,729,000,000	-3,988,000,000	-2,367,000,000	-4,256,000,000	-3,804,000,000	-3,582,000,000	-5,039,000,000	-8,713,000,000	-3,851,000,000	-5,555,000,000	-6,825,000,000	-4,914,000,000	-4,259,000,000	-2,639,000,000	-1,620,000,000	-1,684,000,000	-1,382,000,000	-1,370,900,000	-1,590,900,000	-1,302,500,000	-2,932,700,000
proceeds from sales of securities and other investments	601,000,000	456,000,000	7,000,000	50,000,000	60,000,000	260,000,000	169,000,000	704,000,000	285,000,000	500,000,000	12,000,000	335,000,000	373,000,000	1,000,000	529,000,000	111,000,000	0	386,000,000	918,000,000	2,000,000	76,000,000	1,816,000,000	1,163,000,000	2,524,000,000	3,036,000,000	1,899,000,000	4,009,000,000	3,840,000,000	5,555,000,000	1,848,000,000	3,131,000,000	3,170,000,000	2,544,000,000	6,819,000,000	3,053,000,000	3,912,000,000	2,768,000,000	4,620,000,000	3,882,000,000	3,903,000,000	6,341,000,000	6,287,000,000	3,307,000,000	3,705,000,000	5,470,000,000	2,632,000,000	6,475,000,000	2,628,000,000	1,409,000,000	1,850,000,000	1,366,000,000	1,524,000,000	834,700,000	2,026,700,000	1,426,900,000	272,700,000
acquisition of harpoon therapeutics, inc., net of cash acquired			0	0	0	-746,000,000
net cash from investing activities	-770,000,000	-1,487,000,000	-1,444,000,000	-3,845,000,000	-1,069,000,000	-1,376,000,000		-334,000,000	-11,443,000,000	-2,359,000,000					0	0	604,000,000	-738,000,000	-4,778,000,000	-2,155,000,000	-882,000,000	-1,628,000,000	-763,000,000	191,000,000	-2,425,000,000	368,000,000	2,178,000,000	1,660,000,000	673,000,000	-197,000,000	-58,000,000	671,000,000	-1,127,000,000	3,193,000,000	-2,563,000,000	-890,000,000	-1,498,000,000	1,741,000,000	-617,000,000	-61,000,000	2,525,000,000	-6,605,000,000	7,204,000,000	-3,722,000,000	-49,000,000	-3,807,000,000	1,177,000,000	-2,037,000,000	-1,684,000,000	-263,000,000	-1,048,000,000	105,000,000	-1,007,500,000	194,800,000			-861,000,000
cash flows from financing activities
net change in short-term borrowings															-3,000,000	0	-4,771,000,000	788,000,000	2,860,000,000	-2,278,000,000	-1,616,000,000	3,583,000,000	182,000,000	-360,000,000	603,000,000	-4,135,000,000	2,830,000,000	225,000,000	2,070,000,000	-1,000,000	-1,988,000,000	1,986,000,000	-3,808,000,000	3,784,000,000		918,000,000			-14,000,000	3,000,000	-3,706,000,000	2,177,000,000	-3,537,000,000	4,963,000,000	-5,035,000,000	3,149,000,000	-310,000,000	-1,551,000,000	-280,000,000	-40,000,000	1,593,000,000	-197,000,000	-1,483,000,000	-84,700,000	-962,700,000	2,620,400,000	-2,000,000		-167,000,000	-4,000,000	-36,000,000
proceeds from issuance of debt			0	-1,000,000			0	-7,000,000											0	-26,000,000			0	0	0	4,958,000,000									1,071,000,000	0			0	-2,000,000	-1,000,000	7,941,000,000	3,145,000,000	0			0	0
payments on debt	0	-2,500,000,000	-539,000,000	0	0	-751,000,000	-3,000,000	-1,000,000	-1,750,000,000	-1,000,000	-1,000,000	-1,000,000,000	0	-1,250,000,000	-1,166,000,000	0	0	-1,153,000,000	-3,000,000	-2,000,000	-1,000,000	-1,951,000,000					-1,280,000,000	1,000,000	-2,005,000,000	-1,003,000,000	-802,000,000	0	-1,000,000	-300,000,000	0	-35,000,000	-1,500,000,000	-851,000,000	-1,000,000	0	-3,000,000	-2,902,000,000	-6,610,000,000	-2,000,000	-2,000,000	-3,000,000	-1,260,000,000	0	-270,000,000	-12,000,000	-1,261,000,000	-4,000,000	-651,700,000	-63,200,000	-3,800,000	-622,300,000
dividends paid to stockholders	-2,077,000,000	-2,050,000,000	-1,951,000,000	-1,953,000,000	-1,986,000,000	-1,950,000,000	-1,852,000,000	-1,855,000,000	-1,885,000,000	-1,853,000,000	-1,750,000,000	-1,747,000,000	-1,770,000,000	-1,745,000,000	-1,643,000,000	-1,649,000,000	-1,673,000,000	-1,645,000,000	-1,542,000,000	-1,545,000,000	-1,577,000,000	-1,551,000,000	-1,405,000,000	-1,394,000,000	-1,468,000,000	-1,428,000,000	-1,277,000,000	-1,285,000,000	-1,311,000,000	-1,299,000,000	-1,283,000,000	-1,283,000,000	-1,307,000,000	-1,294,000,000	-1,271,000,000	-1,274,000,000	-1,300,000,000	-1,279,000,000	-1,263,000,000	-1,272,000,000	-1,302,000,000	-1,280,000,000	-1,259,000,000	-1,282,000,000	-1,339,000,000	-1,290,000,000	-1,260,000,000	-1,259,000,000	-1,165,000,000	-1,175,000,000	-1,176,000,000	-1,175,000,000	-1,174,800,000	-1,181,300,000	-1,189,300,000	-1,188,600,000
purchases of treasury stock	-1,345,000,000	-1,164,000,000	-489,000,000	-444,000,000	-251,000,000	-122,000,000	-393,000,000	-466,000,000	-338,000,000	-149,000,000					-18,000,000	-583,000,000			0	0	0	-1,281,000,000	-1,050,000,000	-1,405,000,000	-1,235,000,000	-1,090,000,000	-5,933,000,000	-996,000,000	-1,596,000,000	-566,000,000	-1,702,000,000	-159,000,000	-1,134,000,000	-1,019,000,000	-1,016,000,000	-845,000,000	-660,000,000	-913,000,000	-1,181,000,000	-1,281,000,000	-709,000,000	-1,015,000,000	-1,620,000,000	-2,670,000,000	-2,246,000,000	-1,167,000,000	-196,000,000	-215,000,000	-562,000,000	-1,045,000,000			300,000	-296,100,000
proceeds from exercise of stock options	12,000,000	19,000,000	12,000,000	5,000,000	73,000,000	87,000,000	6,000,000	7,000,000	82,000,000	30,000,000	265,000,000	10,000,000	97,000,000	12,000,000	134,000,000	17,000,000	42,000,000	9,000,000	21,000,000	28,000,000	14,000,000	26,000,000	17,000,000	40,000,000	131,000,000	173,000,000	130,000,000	162,000,000	69,000,000	230,000,000	18,000,000	73,000,000	95,000,000	313,000,000	149,000,000	409,000,000	179,000,000	202,000,000	51,000,000	57,000,000	135,000,000	242,000,000	179,000,000	247,000,000	203,000,000	931,000,000	401,000,000	168,000,000	127,000,000	32,000,000	125,000,000	37,000,000	50,100,000	75,700,000	41,900,000	195,300,000
net cash from financing activities	-3,556,000,000	-5,755,000,000	-3,009,000,000	-2,425,000,000	1,216,000,000	-2,814,000,000		-4,269,000,000	3,758,000,000	-2,054,000,000					0	0	1,594,000,000	-2,098,000,000	1,372,000,000	-3,851,000,000	1,137,000,000	-1,490,000,000	-2,011,000,000	-3,152,000,000	-2,084,000,000	-1,614,000,000	-5,566,000,000	-1,905,000,000	-2,967,000,000	-2,722,000,000	-5,785,000,000	536,000,000	-6,218,000,000	1,461,000,000	-1,977,000,000	-835,000,000	-3,381,000,000	-2,851,000,000	-2,407,000,000	-2,533,000,000	-5,485,000,000	5,155,000,000	-9,643,000,000	1,279,000,000	-8,369,000,000	1,620,000,000	-2,624,000,000	-2,915,000,000	-2,231,000,000	-2,244,000,000	-1,257,000,000	-1,172,000,000	-1,294,900,000	-1,625,000,000			-181,000,000			-465,000,000	-184,000,000
effect of exchange rate changes on cash, cash equivalents and restricted cash	374,000,000	156,000,000	-367,000,000	294,000,000	-82,000,000	-138,000,000	186,000,000	-157,000,000	-93,000,000	87,000,000	366,000,000	-412,000,000	-309,000,000	-55,000,000	-68,000,000	-46,000,000	78,000,000	-97,000,000	164,000,000	87,000,000	65,000,000	-63,000,000	43,000,000	-54,000,000	8,000,000	20,000,000	-65,000,000	-32,000,000	-262,000,000	154,000,000
net increase in cash, cash equivalents and restricted cash			-1,370,000,000	3,315,000,000			-1,760,000,000	2,957,000,000	-4,074,000,000	-2,987,000,000	1,494,000,000	1,526,000,000	1,139,000,000	447,000,000	-1,879,000,000	1,416,000,000					3,687,000,000	-2,474,000,000	2,063,000,000			110,000,000	139,000,000	2,516,000,000	826,000,000	-1,610,000,000
cash, cash equivalents and restricted cash at beginning of year	0	13,318,000,000	0	0	0	6,909,000,000	0	0	0	12,773,000,000	0	0	0	8,167,000,000	0	0	-12,000,000	8,165,000,000	0	0	0	9,934,000,000	0	0	0	7,967,000,000	0	0	0	6,096,000,000
cash, cash equivalents and restricted cash at end of period	-659,000,000	8,732,000,000		3,315,000,000	5,702,000,000	5,671,000,000		2,957,000,000	-4,074,000,000	9,786,000,000		1,526,000,000	1,139,000,000	8,614,000,000		1,416,000,000	1,607,000,000	7,023,000,000		-3,746,000,000	3,687,000,000	7,460,000,000		1,211,000,000	-1,417,000,000	8,077,000,000		2,516,000,000	826,000,000	4,486,000,000
alliance revenue - lynparza	58,000,000	312,000,000			25,000,000	292,000,000		-11,000,000	35,000,000	275,000,000
alliance revenue - koselugo	-1,000,000	44,000,000			-1,000,000	38,000,000		1,000,000	2,000,000	23,000,000
total alliance revenue	57,000,000	356,000,000			24,000,000	330,000,000		-10,000,000	37,000,000	298,000,000
cost of sales	3,000,000	83,000,000			0	82,000,000		4,000,000	8,000,000	70,000,000
selling, general and administrative	8,000,000	32,000,000			4,000,000	39,000,000		-7,000,000	4,000,000	47,000,000
research and development	4,000,000	12,000,000			-2,000,000	20,000,000		1,000,000	1,000,000	21,000,000
receivables from astrazeneca included in other current assets		358,000,000				334,000,000				303,000,000
payables to astrazeneca included in accrued and other current liabilities		15,000,000				617,000,000				21,000,000
net decrease in cash, cash equivalents and restricted cash		-4,586,000,000				-1,238,000,000												-1,142,000,000
intangible asset impairment charges							779,000,000				839,000,000	887,000,000							1,683,000,000	15,000,000			176,000,000	612,000,000	148,000,000	104,000,000					270,000,000	245,000,000	51,000,000	80,000,000	3,376,000,000	5,000,000	290,000,000	277,000,000	82,000,000	7,000,000	59,000,000	14,000,000	13,000,000	549,000,000			171,000,000	0	244,000,000	22,000,000
(income) income from investments in equity securities							-100,000,000	34,000,000	176,000,000	-450,000,000
charges for certain research and development asset acquisitions
net changes in assets and liabilities:
accounts receivable																																																									-292,000,000	223,000,000	275,000,000	-24,000,000	-383,000,000
inventories																																																									-239,000,000	161,000,000	-23,000,000	26,000,000	-138,000,000
trade accounts payable
accrued and other current liabilities
income taxes payable
noncurrent liabilities
proceeds from sale of seagen inc. common stock
acquisition of eyebiotech limited, net of cash acquired			0
acquisition of elanco animal health incorporated aqua business			-2,000,000
acquisition of mk-1045 from curon pharmaceutical
acquisition of prometheus biosciences, inc., net of cash acquired							0	0
acquisition of imago biosciences inc., net of cash acquired
cash, cash equivalents and restricted cash at end of year
property, plant and equipment
product rights - clynav
other product rights
other assets and liabilities
total identifiable net assets
goodwill
consideration transferred
charge for the acquisition of eyebiotech limited
charge for the acquisition of mk-1045 (formerly cn201) from curon pharmaceutical
charge for the acquisition of harpoon therapeutics, inc.				0	0	656,000,000
charge for the acquisition of prometheus biosciences, inc.							0	0
charge for the acquisition of imago biosciences, inc.							0	0	0	1,192,000,000
acquisition of mk-1045 (formerly cn201) from curon pharmaceutical
acquisition of imago biosciences, inc., net of cash acquired								0	0	-1,327,000,000
payables to astrazeneca included in other noncurrent liabilities										600,000,000
cash flows from operating activities of continuing operations
net income from continuing operations											3,018,000,000	3,252,000,000	3,949,000,000	4,307,000,000	3,824,000,000	4,571,000,000
adjustments to reconcile net income from continuing operations to net cash from operating activities of continuing operations:
charge for the acquisition of pandion therapeutics, inc.															0	0
net cash from operating activities of continuing operations											4,430,000,000	5,602,000,000	4,302,000,000	4,761,000,000
cash flows from investing activities of continuing operations
acquisition of acceleron pharma inc., net of cash acquired
acquisition of pandion therapeutics, inc., net of cash acquired
other acquisitions, net of cash acquired											0				-90,000,000	1,000,000	-76,000,000	-14,000,000	-458,000,000	-586,000,000			-25,000,000	1,000,000
net cash from investing activities of continuing operations											-1,748,000,000	-962,000,000	-1,077,000,000	-1,173,000,000
cash flows from financing activities of continuing operations
distribution from organon & co.															0	0
net cash from financing activities of continuing operations											-1,554,000,000	-2,702,000,000	-1,777,000,000	-3,086,000,000
cash flows from discontinued operations
net cash flows from discontinued operations															-64,000,000	0
cash and cash equivalents
investments
identifiable intangible assets:
ipr&d - sotatercept
product rights - reblozyl
deferred income tax liabilities
loss (income) from investments in equity securities											58,000,000	370,000,000	283,000,000	708,000,000
charge for the acquisition of velosbio inc.
purchase of seagen inc. common stock
acquisition of velosbio inc., net of cash acquired
acquisition of arqule, inc., net of cash acquired																			0	0	0	-2,545,000,000
less: cash and cash equivalents related to discontinued operations
years ended december 31
sales
costs, expenses and other
restructuring costs
other income
income from discontinued operations before taxes
tax provision
income from discontinued operations, net of taxes
less: income of discontinued operations attributable to noncontrolling interests
income tax benefit
charge for the acquisition of peloton therapeutics, inc.
acquisition of antelliq corporation, net of cash acquired																							0	0
acquisition of peloton therapeutics, inc., net of cash acquired																							0
discontinued operations
adjustments to reconcile net income from continuing operations to net cash from operating activities:
net cash from operating activities from continuing operations																4,797,000,000
acquisition of pandion therapeutics, inc. net of cash acquired																0
net cash from investing activities from continuing operations																-1,061,000,000
net cash from financing activities from continuing operations																-2,274,000,000
charge for future payments related to collaboration license options																											0
depreciation and amortization																				852,000,000	1,048,000,000	821,000,000	936,000,000	845,000,000	973,000,000	898,000,000	1,095,000,000	1,061,000,000	1,226,000,000	1,137,000,000	1,128,000,000	1,154,000,000	1,162,000,000	1,193,000,000	1,155,000,000	1,175,000,000	1,550,000,000	1,561,000,000	1,560,000,000	1,570,000,000	1,608,000,000	1,637,000,000	1,573,000,000	1,611,000,000	1,753,000,000	1,754,000,000	1,954,000,000	1,705,000,000	1,861,000,000	1,903,000,000	1,832,000,000	1,831,000,000	1,866,000,000	1,879,900,000	1,947,700,000	1,687,400,000	296,000,000		394,000,000	543,000,000	876,000,000
charge for acquisition of peloton therapeutics, inc.
provisional charge for one-time transition tax related to the enactment of u.s. tax legislation
charge for collaboration termination
charge related to the settlement of worldwide keytruda patent litigation
acquisitions, net of cash acquired																											-59,000,000
charge for future payments related to eisai collaboration license options																													0	650,000,000
acquisitions of businesses, net of cash acquired																																0	-41,000,000	-306,000,000															0	0			-104,200,000	-10,500,000	-10,000,000	-131,300,000
charge for future payments related to astrazeneca collaboration license options																															-250,000,000
foreign currency devaluation related to venezuela																																							161,000,000
net charge related to the settlement of vioxx shareholder class action litigation
equity income from affiliates																																			-27,000,000	-21,000,000	-4,000,000	-34,000,000	5,000,000	-63,000,000	-2,000,000	-145,000,000	-16,000,000	-24,000,000	-93,000,000	-124,000,000	-53,000,000	-102,000,000	-256,000,000	-161,000,000	-55,000,000	-138,000,000	-170,200,000	-236,400,000	-42,900,000	-137,500,000
dividends and distributions from equity method affiliates
acquisition of cubist pharmaceuticals, inc., net of cash acquired																																							0	0	0	-7,598,000,000
acquisitions of other businesses, net of cash acquired																																			-2,000,000	-621,000,000	-10,000,000	-147,000,000	-36,000,000
dispositions of businesses, net of cash divested																																								126,000,000				490,000,000	25,000,000	533,000,000			0	0	17,000,000	306,000,000
effect of exchange rate changes on cash and cash equivalents																															19,000,000	79,000,000	106,000,000	253,000,000	-484,000,000	53,000,000	156,000,000	144,000,000	-247,000,000	-85,000,000	-683,000,000	-295,000,000	-326,000,000	-278,000,000	18,000,000	33,000,000	-48,000,000	3,000,000	-40,000,000	-159,000,000	100,000,000	141,000,000	-210,700,000	47,100,000	104,200,000	-235,600,000
net increase in cash and cash equivalents																															-1,809,000,000	115,000,000	-3,922,000,000	5,193,000,000	-1,392,000,000			1,192,000,000	976,000,000			539,000,000	-3,929,000,000	1,627,000,000	-6,085,000,000	207,000,000	1,531,000,000	-1,000,000,000	-722,000,000	1,911,000,000	647,000,000	795,000,000	1,026,000,000	1,208,800,000	429,600,000	-1,075,400,000			454,000,000
cash and cash equivalents at beginning of year																															0	0	0	6,515,000,000	0	0	0	8,524,000,000	0	0	0	7,441,000,000	0	0	0	15,621,000,000	0	0	0	0	0	10,900,000,000	-400,000	0	0	9,311,400,000
cash and cash equivalents at end of year
cash and cash equivalents at end of period																																115,000,000	-3,922,000,000	11,708,000,000		1,299,000,000	-3,108,000,000	9,716,000,000		626,000,000	-1,058,000,000	7,980,000,000		1,627,000,000	-6,085,000,000	15,828,000,000		-1,000,000,000		1,911,000,000	647,000,000	11,695,000,000		1,208,800,000	429,600,000	8,236,000,000
gain on divestiture of merck consumer care business
gain on astrazeneca option exercise																																											0	0										0
loss on extinguishment of debt
divestiture of merck consumer care business, net of cash divested
dispositions of other businesses, net of cash divested
proceeds from astrazeneca option exercise																																											0	0										0
acquisition of idenix pharmaceuticals, inc., net of cash acquired																																											0
acquisition of bayer ag collaboration rights
cash inflows from net investment hedges
other dividends paid
dividends and distributions from equity affiliates																																				5,000,000	3,000,000	4,000,000		5,000,000	4,000,000	3,000,000		7,000,000	59,000,000	66,000,000	59,000,000	110,000,000	30,000,000	65,000,000	56,000,000	65,000,000	60,200,000	81,700,000	104,700,000	77,400,000
net decrease in cash and cash equivalents
foreign exchange losses related to venezuela
gain on divestiture of merck consumer care
divestiture of consumer care business, net of cash divested
gain on divestiture of certain ophthalmic products
gain on disposition of interest in equity method investment
proceeds from sale of interest in equity method investment
cash inflows (outflows) from net investment hedges
gain on astrazeneca lp asset option exercise
proceeds from astrazeneca lp asset option exercise
decrease in restricted assets
gain related to merck/schering-plough partnership
schering-plough merger, net of cash acquired
supplemental cash flow information
gain on astrazeneca asset option exercise
in-process research and development impairment charges																																																				302,000,000
increase in restricted assets																																																						200,000	18,100,000	-25,100,000
gains on distributions from astrazeneca lp
gain on disposition of interest in merial limited
proceeds from sale of interest in merial limited
distributions from astrazeneca lp
decrease (increase) in restricted assets
proceeds from the issuance of debt																																																						0
net cash (used by) provided by investing activities																																																								-3,148,100,000
net cash from (used by) financing activities																																																								942,200,000
gain on distribution from astrazeneca lp
u.s. vioxx settlement agreement charge
in-process research and development
taxes paid for internal revenue service settlement
distribution from astrazeneca lp
net cash from (used by) investing activities
net cash used by financing activities
operating activities:
accrued share-based compensation																																																									48,000,000		52,000,000	58,000,000	60,000,000
special, merger and acquisition-related charges and payments																																																									-8,000,000
gain on sale of divested products
changes in assets and liabilities:
prepaid expenses and other assets																																																									47,000,000	24,000,000	-8,000,000	-92,000,000	78,000,000
accounts payable																																																									88,000,000		37,000,000
other liabilities																																																									-189,000,000		-22,000,000
investing activities:
dispositions of property and equipment																																																									1,000,000		2,000,000	4,000,000	27,000,000
contributions to benefit-related trusts
proceeds from divested products
purchases of short-term investments																																																									-708,000,000
maturities of short-term investments																																																									5,000,000		17,000,000	-15,000,000	25,000,000
financing activities:
payments of long-term debt																																																									-71,000,000		-466,000,000
cash dividends paid to common shareholders																																																									-106,000,000		-106,000,000	-106,000,000	-105,000,000
cash dividends paid to preferred shareholders																																																									-38,000,000		-38,000,000	-37,000,000	-38,000,000
stock option exercises																																																									36,000,000		11,000,000	2,000,000	2,000,000
effect of exchange rates on cash and cash equivalents																																																									-42,000,000		-55,000,000	0	20,000,000
cash and cash equivalents, beginning of period																																																									3,373,000,000	-1,788,000,000	0	0	2,279,000,000
cash and cash equivalents, end of period																																																									2,845,000,000	-2,955,000,000	454,000,000	251,000,000	2,454,000,000
net (decrease)/increase in cash and cash equivalents
net (decrease) / increase in cash and cash equivalents																																																									-528,000,000
income from operations
adjustments to reconcile income from operations to net cash from operating activities:
rebates payable
payable to merck and schering-plough
accrued expenses and other liabilities
non-cash charges
contributions from partners
distributions to partners
net increase/(decrease) in cash and cash equivalents																																																													175,000,000
balance, january 1, 2006
balance, december 31, 2006
balance, december 31, 2007
balance, december 31, 2008
special and acquisition-related charges and payments																																																											57,000,000
purchases of derivative instruments
change in fair value of foreign currency option
payments to u.s. taxing authorities
net cash (used for)/provided by investing activities																																																											85,000,000	-206,000,000	-123,000,000
proceeds from preferred stock issuance
proceeds from common stock issuance
issuance of long-term debt
net cash (used for)/provided by financing activities
purchase of derivative currency option
accounts payable and other liabilities																																																													-322,000,000
net cash provided by/(used for) operating activities																																																													462,000,000
balance, january 1, 2005
balance, december 31, 2005

We provide you with 20 years of cash flow statements for Merck & Co. stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Merck & Co. stock. Explore the full financial landscape of Merck & Co. stock with our expertly curated income statements.

The information provided in this report about Merck & Co. stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.